Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | MET | P08581 | 2/20 | 0.47 |
| ▸ | APP | P05067 | 2/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL371566 | 0.89 | PDGFRB (0.63) | CYP3A4CYP1A2CYP2C19TP53NPC1 | |
| SCHEMBL14396638 | 0.85 | RAB9A (0.61) | CYP3A4CYP1A2CYP2C19TP53NPC1 | |
| SCHEMBL19957105 | 0.82 | KDR (0.65) | CYP3A4CYP1A2CYP2C19DDR2PDGFRB | |
| SCHEMBL22358 | 0.82 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19TP53NPC1 | |
| SCHEMBL29683488 | 0.82 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19TP53NPC1 | |
| Hydrochloric Acid SCHEMBL11423357 | 0.80 | CYP3A4 (0.97) | CYP3A4CYP1A2CYP2C19TP53NPC1 | |
| Hydrochloric Acid SCHEMBL11151690 | 0.80 | CYP3A4 (0.97) | CYP3A4CYP1A2CYP2C19TP53NPC1 | |
| Ammonia Solution, Strong SCHEMBL7998249 | 0.80 | CYP3A4 (0.97) | CYP3A4CYP1A2CYP2C19TP53NPC1 | |
| SCHEMBL7286497 | 0.79 | CYP3A4 (0.82) | CYP3A4CYP1A2CYP2C19TP53NPC1 | |
| SCHEMBL21186212 | 0.77 | CYP3A4 (0.68) | CYP3A4CYP1A2CYP2C19TP53NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7626030-B2 | Compounds and methods of use | AMGEN INC. (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1711495-A2 | QUINOLINE, QUINAZOLINE, PYRIDINE AND PYRIMIDINE COUNDS AND THEIR USE IN THE TREATMENT OF INFLAMMATION, ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20050245547-A1 | 6-((6,7-Bis(methoxy)-4-quinolinyl)oxy)-N-(3-methylphenyl)-1-benzofuran-3-carboxamide;antiproliferative; -metastasis; -carcinogenic; -tumor; -inflammatory; -arthritic agents;hypotensive agents; myocardium necrosis; rheumatic diseases; tyrosine kinase inhibitors; antiallergens; asthma | AMGEN INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005073224-A2 | QUINOLINE QUINAZOLINE PYRIDINE AND PYRIMIDINE COUNDS AND THEIR USE IN THE TREATMENT OF INFLAMMATION ANGIOGENESIS AND CANCER | AMGEN INC (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245547-A1 | 6-((6,7-Bis(methoxy)-4-quinolinyl)oxy)-N-(3-methylphenyl)-1-benzofuran-3-carboxamide;antiproliferative; -metastasis; -carcinogenic; -tumor; -inflammatory; -arthritic agents;hypotensive agents; myocardium necrosis; rheumatic diseases; tyrosine kinase inhibitors; antiallergens; asthma | HGF, MET, HGFAC | CYP3A4 1110/4885CYP1A2 1075/4885CYP2C19 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.